# Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration?

> **NCT06922656** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Dasman Diabetes Institute** · enrollment: 60 (estimated)

## Conditions studied

- Type 1 Diabetes

## Interventions

- **DRUG:** Dapagliflozin (DAPA)
- **DRUG:** Pioglitazone 45 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06922656
- **Lead sponsor:** Dasman Diabetes Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-15
- **Primary completion:** 2026-09-01
- **Final completion:** 2027-01-15
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06922656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06922656, "Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration?". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06922656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*